Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
Date:11/3/2009

accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income."

"Delivering another quarter of strong financial performance points to our success in building Nexavar as an oncology blockbuster and demonstrates our commitment to executing on our strategic priorities," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "As the next step in our plans to grow the company strategically, we recently announced our intention to acquire Proteolix Inc., a leader in the science of proteasome inhibition. Through continued investigation of Nexavar in a broad array of additional tumor types and investment in a growing number of pipeline candidates, we are creating multiple opportunities for additional value creation."

Revenue from Collaboration Agreement

For the third quarter 2009, Onyx reported revenue from its Nexavar collaboration agreement of $69.1 million compared to $50.8 million for the same period in 2008. The 36% increase in revenue from collaboration agreement between periods resulted from an increase in Nexavar sales and royalty revenue and a decrease in Nexavar commercial expenses.

Operating Expenses

Onyx recorded research and development expenses of $35.6 million in the third quarter 2009, compared to $21.8 million for the same period in 2008. Higher research and development expenses in the third quarter 2009 were primarily due to planned increases in the development program for Nexavar across additional tumor types, such as thyroid, colorectal and adjuvant liver cancer and Onyx's costs to further develop ONX 0801, including a milestone payment of $7.0 million to BTG International Limited. Selling, general and administrative expenses were $23.4 million in the third quarter 2009, compared to $19.3 million for the same period in 2008. Higher selling, general and administrative expenses were primarily due to headcount-related expenses to support Onyx's growth.
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
2. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
3. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
4. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
5. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
6. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
7. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
8. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
9. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
10. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
11. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... (PRWEB) July 29, 2014 Award-winning inventor Michael ... a flatulence neutralizer specifically designed to absorb embarrassing odors in ... that can easily be stored in a desk drawer. This ... the PoofPad, users will simply sit on the pad and ... at the office and then BAM, someone appears out of ...
(Date:7/29/2014)... July 29, 2014 "Acceptance, Recognition, and ... who faced his own demons and wants other men to ... life partner left. A month later, he had no job, ... pay. When Raymond approached the government for assistance, the emotional ... two-year counselling program. But this approach didn’t get to the ...
(Date:7/29/2014)... Current Back2Basics long-term drug rehab resident Jon B. ... his first six months of sobriety. , This was ... foot, once on the other– which was how he became ... ago and was prescribed drugs that I didn’t take properly.” ... home who’d recently completed the program. The six-month long residential ...
(Date:7/29/2014)... Consilium Staffing, Your Partner in Locum Tenens, is ... of 2014, with strong indications the Irving, Texas-based firm will ... year. , “This is a great time to be at ... , “We are proud of what we have accomplished ... even more excited about how things are shaping up for ...
(Date:7/29/2014)... July 29, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
Breaking Medicine News(10 mins):Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2Health News:Back2Basics Sober Living Resident Overcomes Obstacle in Early Sobriety 2Health News:Consilium Staffing Experiences Significant Revenue Growth 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... release is available in French . , ... on possible links between cell phone use and brain ... collaborated on the Interphone International Study Group. Jack Siemiatycki, ... epidemiologist at the University of Montreal Hospital Research Center, ...
... HACKENSACK, N.J. (May 17, 2010) John Theurer Cancer Center ... is one of two cancer centers in the tri-state ... DVS (Dose Verification System). John Theurer Cancer Center radiation ... the precise amount of radiation being delivered to tumors ...
... could pave way for tests that predict the illness, researchers ... of serious lung disease in middle age may have genetic ... history of such illnesses in their background, a new study ... might enable doctors to screen for genetic predispositions to serious ...
... ... in the May 17 – 21 event , ... (PRWEB) May 17, 2010 -- Pedego® Electric Bicycles has ... throughout Northern California, has added the Pedego Comfort Cruiser line of electric bikes to ...
... ... keep Affiliates informed on how to achieve the highest conversion performance. , ... Encino, CA (PRWEB) May 14, ... technology concerning the affiliate marketing industry. Founded in 2006, T3Leads has since provided unparalleled ...
... ... Patients Reverse Sun Damage and Restore the Health of Their Skin without Painful Surgery ... Los Angeles ... damage, resulting in wrinkles, sagging, age spots, discoloration and other unsightly symptoms. While a ...
Cached Medicine News:Health News:World's biggest study on cell phones and brain cancer inconclusive 2Health News:John Theurer Cancer Center offers breakthrough radiation measurement technology 2Health News:Lung Disease Can Be Genetic Even Without Family History 2Health News:T3Leads Provides Latest Industry News: Imperative Information to Help Publishers Maximize Profits 2Health News:T3Leads Provides Latest Industry News: Imperative Information to Help Publishers Maximize Profits 3Health News:Epione Reveals a ‘Bright' New Solution for Dull, Sun Damaged Skin 2
(Date:7/28/2014)... 28, 2014   Stone & Magnanini LLP ... marketing and fraud claims between the United States ... ("VSI").  The settlement covers fraud in connection with ... laser ablation of varicose veins for unapproved uses. ... a history of representing whistleblowers in groundbreaking settlements, ...
(Date:7/28/2014)... /PRNewswire-iReach/ -- June 28 th , 2014 – Oncolab, the ... AMAS cancer test, is making its AACC debut (booth #4051) ... which is a serum-based in vitro immunoassay, has been run ... tool in the fight against cancer recurrence. Photo ... 17 million cancer survivors in the US alone, the race ...
(Date:7/28/2014)... , July 28, 2014 Reportlinker.com announces ... in its catalogue: Portugal Pharmaceuticals ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes ... View: Faster-than-expected economic growth last quarter has led ... slightly upwards. As forecast previously, BMI expects ...
Breaking Medicine Technology:Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4
... Hospira, Inc. (NYSE: HSP ... announced positive results from a Phase I U.S. clinical ... renal (kidney) dysfunction who have anemia. Hospira,s trial met ... and distribution in the body, for Hospira,s EPO and ...
... 6, 2011 Omthera Pharmaceuticals, Inc., a privately-held emerging ... and Chief Executive Officer, will present at the Rodman ... 2011 at 2:25pm ET at the Waldorf Astoria Hotel ... Pharmaceuticals, Inc. Founded in 2008, Omthera ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: